• Events
  • Panel discussion: World Health Summit 2019: Building Capacities...
Panel discussion - Event date: 28 Oct 2019

World Health Summit 2019: Building Capacities and Strong Institutions in Africa

On Monday 28 October, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, will join a keynote panel at the 2019 World Health Summit in Berlin. 

Jayasree will join the panel titled 'Focus Africa: Building Capacities and Strong Institutions' . The keynote panel is hosted by Makerere University and chaired by the Principal of the University, Professor Charles Ibingira. The panel will take place on Monday 28 October at 14:00 in Saal 1 (Rudolf Virchow).

As the World Health Summit notes, the African Union has made health one of its priorities. It sees increasing political commitment to invest in health in a number of African countries. New institutions have been built – such as the African Centers for Disease Control – and primary health care is in the focus. There are new initiatives to support African-led innovation coalitions and innovative funding platforms and to strengthen research institutions. This requires additional investments in science, technology, and innovation in Africa to improve health, spur economic growth, and reduce poverty across the continent.


  • H.E. Dr. Jane Ruth Aceng, Ministry of Health, Minister of Health, Uganda
  • Thomas Cueni, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Director-General, Switzerland
  • Dr. Jayasree K. Iyer, Access to Medicine Foundation, Executive Director, The Netherlands
  • Dr. Matshidiso Rebecca Moeti, World Health Organization (WHO), WHO Regional Office for Africa, Regional Director for Africa, Republic of the Congo
  • Dr. Gerd Müller, Federal Ministry for Economic Cooperation and Development (BMZ), Federal Minister of Economic Cooperation and Development, Germany

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |